Smart measurement of circulating tumor DNA: a tumor-agnostic computational tool to improve colorectal cancer care

Smart measurement of circulating tumor DNA: a tumor-agnostic computational tool to improve colorectal cancer care - the SMART study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON57448

Enrollment

100

Registered

2025-04-29

Start date

2025-12-05

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer malignant tumors

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: (suspect) LS carriers who: - Have proven Lynch Syndrome (MMR gene or EpCAM mutation); - Have been diagnosed with any form of cancer at time of inclusion, but have had treatment yet

Exclusion criteria

Exclusion criteria: (suspect) LS carriers who: - Are unwilling to undergo extra blood sampling; - Have no newly diagnosed tumors at time of inclusion; - Have been treated for their tumor at time of inclusion.

Design outcomes

Primary

Measure	Time frame
The agreement between estimated ctDNA fractions and the presence of cancer.	—

Secondary

Measure	Time frame
N.A.	—

Countries

Netherlands

Outcome results